Treating Tuberculosis Meningitis with High-Dose Oral Rifampin
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on January 30th, 2026
|
Treating tuberculosis meningitis is challenging due to the complicated medical regimen, the increased prevalence of resistance, and the medication inability to penetrate into the cerebrospinal fluid. This resulted in a lower clinical outcome and a high mortality rate in patients with HIV comorbidity. A study funded by the U.K. Medical Research Council, was conducted to assess the usage of a high-dose rifampin regimen to treat tuberculosis meningitis.
The clinical study was conducted in Indonesia, South Africa, Uganda, and it included 499 participants who had been diagnosed with tuberculosis meningitis. This clinical diagnosis was defined with a cerebrospinal fluid sample that is microbiologically positive when tested with the Xpert MTB/RIF Ultra assay. Testing of the CSF found that the cohort has a median white-cell count between 50 and 60 cells per cubic millimeter. Symptom assessment with the MRC disease severity scale found that around 17% of them had the most severe form of disease, with the patient’s consciousness, verbal, and motor responses diminished heavily. Around 60% of the participants were infected with HIV, 40% of whom were using antiretroviral therapy.
The participants were randomly assigned to be treated with either the standard rifampin dose of 10 mg or the high rifampin dose of 35 mg for the first 8 weeks. The dose was then set to 10 mg for all participants for the remaining 9 to 12 months. In addition to rifampin, all patients were treated with the other standard anti-tuberculosis medications such as isoniazid, pyrazinamide, and ethambutol. After the first 6 months, the researchers found that there is a small, but not statistically reduction in the survival rate in patients treated with the experimental higher 35 mg dose, when compared to the standard 10 mg rifampin. This lack of clinical benefit is true regardless of their disease severity, HIV infection status, antiretroviral therapy usage, or CD4 count. The researchers hypothesized that the higher dose of rifampin might be detrimental to the patient’s survival, as the faster killing of mycobacteria might induce a more potent immunologic reaction, which can result in strong inflammation.
The clinical study was conducted in Indonesia, South Africa, Uganda, and it included 499 participants who had been diagnosed with tuberculosis meningitis. This clinical diagnosis was defined with a cerebrospinal fluid sample that is microbiologically positive when tested with the Xpert MTB/RIF Ultra assay. Testing of the CSF found that the cohort has a median white-cell count between 50 and 60 cells per cubic millimeter. Symptom assessment with the MRC disease severity scale found that around 17% of them had the most severe form of disease, with the patient’s consciousness, verbal, and motor responses diminished heavily. Around 60% of the participants were infected with HIV, 40% of whom were using antiretroviral therapy.
The participants were randomly assigned to be treated with either the standard rifampin dose of 10 mg or the high rifampin dose of 35 mg for the first 8 weeks. The dose was then set to 10 mg for all participants for the remaining 9 to 12 months. In addition to rifampin, all patients were treated with the other standard anti-tuberculosis medications such as isoniazid, pyrazinamide, and ethambutol. After the first 6 months, the researchers found that there is a small, but not statistically reduction in the survival rate in patients treated with the experimental higher 35 mg dose, when compared to the standard 10 mg rifampin. This lack of clinical benefit is true regardless of their disease severity, HIV infection status, antiretroviral therapy usage, or CD4 count. The researchers hypothesized that the higher dose of rifampin might be detrimental to the patient’s survival, as the faster killing of mycobacteria might induce a more potent immunologic reaction, which can result in strong inflammation.